Sponsor:
Merck Sharp & Dohme LLC
Code:
NCT02861573
Conditions
Metastatic Castration-Resistant Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab 200 mg
Olaparib 400 mg
Docetaxel 75 mg/m^2
Prednisone 5 mg
Enzalutamide 160 mg
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations